TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Colorectal cancer
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms BRAVERY TR
- 02 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Mar 2018 New trial record